Randomized multicenter phase II trial of capecitabine versus S-1 as first-line treatment in elderly patients with advanced or recurrent unresectable gastric cancer

Trial Profile

Randomized multicenter phase II trial of capecitabine versus S-1 as first-line treatment in elderly patients with advanced or recurrent unresectable gastric cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2012

At a glance

  • Drugs Capecitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Feb 2010 Actual end date (Jan 2007) added as reported by ClinicalTrials.gov.
    • 16 Feb 2010 Actual patient numbers amended from 91 to 96 as reported by ClinicalTrials.gov.
    • 01 Aug 2008 Primary endpoint 'objective clinical response rate' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top